Patents by Inventor David Aaron Hecht

David Aaron Hecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
    Publication number: 20240124418
    Abstract: Provided herein are phosphodiesterase 4 (PDE4) degraders, e.g., a compound of Formula (I) or (IA), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a PDE4-mediated disease, disorder, or condition.
    Type: Application
    Filed: December 13, 2021
    Publication date: April 18, 2024
    Inventors: Kyle W.H. Chan, Paul E. Erdman, Leah M. Fung, David Aaron Hecht, Frank Mercurio, Robert W. Sullivan, Aparajita Hoskote Chourasia, Patrick Papa
  • SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20240025863
    Abstract: Provided herein are SOS1 protein degraders, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an SOS1-mediated disorder, disease, or condition.
    Type: Application
    Filed: September 16, 2021
    Publication date: January 25, 2024
    Inventors: Kyle W.H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah M. Fung, David Aaron Hecht, Imelda Lam, Patrick Papa, Angela Schoolmeesters, Eduardo Torres
  • PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
    Publication number: 20230071529
    Abstract: Provided herein are phosphodiesterase 4 (PDE4) inhibitors, e.g., a compound of Formula (I) or (II), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disease, disorder, or condition associated with PDE4 malfunction.
    Type: Application
    Filed: December 14, 2020
    Publication date: March 9, 2023
    Applicant: BioTheryX, Inc.
    Inventors: Kyle W.H. Chan, Paul E. Erdman, Leah M. Fung, David Aaron Hecht, Frank Mercurio, Robert W. Sullivan
  • RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20230002371
    Abstract: Provided herein are RAS protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RAS-mediated disorder, disease, or condition.
    Type: Application
    Filed: September 14, 2020
    Publication date: January 5, 2023
    Inventors: Kyle W.H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah M. Fung, David Aaron Hecht, Imelda Lam, Frank Mercurio, Robert W. Sullivan, Eduardo Torres
  • PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20220298172
    Abstract: The present disclosure provides compounds, for example, a compound of Formula (I), that modulate a protein function and/or restore protein homeostasis. The disclosure provides a method of modulating a protein-mediated disease, disorder, condition, or response. Compositions, including in combination with other therapeutic agents, are provided.
    Type: Application
    Filed: May 30, 2022
    Publication date: September 22, 2022
    Applicant: BioTheryX, Inc.
    Inventors: Kyle W.H. Chan, Paul E. Erdman, Aparajita Hoskote Chourasia, Leah M. Fung, David Aaron Hecht, Imelda Lam, Frank Mercurio, Robert W. Sullivan, Eduardo Torres
  • Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications
    Patent number: 11345712
    Abstract: The present disclosure provides compounds, for example, a compound of Formula (I), that modulate a protein function and/or restore protein homeostasis. The disclosure provides a method of modulating a protein-mediated disease, disorder, condition, or response. Compositions, including in combination with other therapeutic agents, are provided.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: May 31, 2022
    Assignee: BioTheryX, Inc.
    Inventors: Kyle W. H. Chan, Paul E. Erdman, Leah Fung, David Aaron Hecht, Imelda Lam, Robert Sullivan, Eduardo Torres
  • BIFUNCTIONAL COMPOUNDS
    Publication number: 20220153751
    Abstract: The present application provides compounds that modulate CDK protein function. Methods of making the compounds, compositions containing the compounds, and uses of the compounds for treating or ameliorating of diseases, disorders, or conditions associated with CDK proteins, are also disclosed.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Applicant: BioTheryX, Inc.
    Inventors: Kyle W.H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah M. Fung, David Aaron Hecht, Frank Mercurio, Robert W. Sullivan, Joseph P. Vacca
  • Bifunctional compounds
    Patent number: 11236103
    Abstract: The present application provides compounds that modulate CDK protein function. Methods of making the compounds, compositions containing the compounds, and uses of the compounds for treating or ameliorating of diseases, disorders, or conditions associated with CDK proteins, are also disclosed.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: February 1, 2022
    Assignee: BioTheryX, Inc.
    Inventors: Kyle W. H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah Fung, David Aaron Hecht, Frank Mercurio, Robert Sullivan, Joseph P. Vacca
  • PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20200369679
    Abstract: The present disclosure provides compounds, for example, a compound of Formula (I), that modulate a protein function and/or restore protein homeostasis. The disclosure provides a method of modulating a protein-mediated disease, disorder, condition, or response. Compositions, including in combination with other therapeutic agents, are provided.
    Type: Application
    Filed: May 26, 2020
    Publication date: November 26, 2020
    Inventors: Kyle W.H. Chan, Paul E. Erdman, Aparajita Hoskote Chourasia, Leah Fung, David Aaron Hecht, Imelda Lam, Frank Mercurio, Robert Sullivan, Eduardo Torres
  • BIFUNCTIONAL COMPOUNDS
    Publication number: 20200048277
    Abstract: The present application provides compounds that modulate CDK protein function. Methods of making the compounds, compositions containing the compounds, and uses of the compounds for treating or ameliorating of diseases, disorders, or conditions associated with CDK proteins, are also disclosed.
    Type: Application
    Filed: July 25, 2019
    Publication date: February 13, 2020
    Inventors: Kyle W.H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah Fung, David Aaron Hecht, Frank Mercurio, Robert Sullivan, Joseph P. Vacca